# Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

> **NCT04778397** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 258 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Idarubicin
- **DRUG:** Steroidal Eye Drops

## Key facts

- **NCT ID:** NCT04778397
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-01
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 258 (ACTUAL)
- **Why stopped:** Study discontinued due to futility.
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04778397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04778397, "Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04778397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*